Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study

Background Chronic nodular prurigo (CNPG) is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous nodules. A comprehensive understanding of this condition, especially regarding its clinical characteristics and impact on quality of life is still...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology Vol. 34; no. 10; pp. 2373 - 2383
Main Authors: Pereira, M.P., Hoffmann, V., Weisshaar, E., Wallengren, J., Halvorsen, J.A., Garcovich, S., Misery, L., Brenaut, E., Savk, E., Potekaev, N., Lvov, A., Bobko, S., Szepietowski, J.C., Reich, A., Bozek, A., Legat, F.J., Metz, M., Streit, M., Serra‐Baldrich, E., Gonçalo, M., Storck, M., Greiwe, I., Nau, T., Steinke, S., Dugas, M., Ständer, S., Zeidler, C., Dalgard, F., Elberling, J., Forner, C., Leslie, T., Riepe, C., Schneider, G., Ständer, H.
Format: Journal Article
Language:English
Published: England 01-10-2020
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Chronic nodular prurigo (CNPG) is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous nodules. A comprehensive understanding of this condition, especially regarding its clinical characteristics and impact on quality of life is still lacking. Objectives Aim of this pan‐European multicentre cross‐sectional study was to establish the clinical profile of CNPG, including its associated burden. Methods Fifteen centres from 12 European countries recruited CNPG patients presenting at the centre or using the centres' own databases. Patients were asked to complete a questionnaire in paper or electronic format. Demography, current co‐morbidities, underlying disease, itch intensity, additional sensory symptoms, quality of life, highest burden and emotional experience of itch were assessed. Results A total of 509 patients (210 male, median age: 64 years [52; 72]) were enrolled. Of these, 406 reported itch and CNPG lesions in the previous 7 days and qualified to complete the whole questionnaire. We recorded moderate to severe worst itch intensity scores in the previous 24 h. Scores were higher in patients with lower educational levels and those coming from Eastern or Southern Europe. Most patients experience itch often or always (71%) and report that their everyday life is negatively affected (53%). Itch intensity was considered to be the most burdensome aspect of the disease by 49% of the patients, followed by the visibility of skin lesions (21%) and bleeding of lesions (21%). The majority of patients was unaware of an underlying condition contributing to CNPG (64%), while psychiatric diseases were the conditions most often mentioned in association with CNPG (19%). Conclusions This multicentre cross‐sectional study shows that itch is the dominant symptom in CNPG and reveals that the profile of the disease is similar throughout Europe.
Bibliography:Conflicts of interest
European Academy of Dermatology and Venereology (EADV, No. 2016‐012 to MP).
MPP, VH, EW, JW, JAH, SG, LM, EB, ES, NP, AL, SB, FJL, MM, MS, ESB, MG, MS, IG, TN, SS, MD, CZ, FD, JE, CF, CR, GS and HS declare no conflicts of interest.MPP is an investigator in a clinical trial sponsored by Trevi and has received speaker honoraria from Galderma and Trevi. JCS is advisor for AbbVie, Almirall, Celgene, Dignity Sciences, LEO Pharma, Novartis, Pierre Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals and Trevi, Toray Corporation, and has received speaker honoraria from AbbVie, Janssen‐Cilag, LEO Pharma, Novartis, SunFarm, Sandoz and Eli Lilly; and clinical trial funding from AbbVie, Almirall, Amgen, Janssen‐Cilag, Menlo Therapeutica, Merck, Novartis, Pfizer, Regeneron, Trevi and UCB. AR is a consultant or speaker for AbbVie, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre‐Fabre, Sandoz and Trevi and a principal investigator or subinvestigator in clinical trials sponsored by AbbVie, Drug Delivery Solutions Ltd, Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer and Trevi. AB is a subinvestigator in clinical trials sponsored by Drug Delivery Solutions Ltd, Genentech, Leo Pharma, Menlo Therapeutics and Trevi. SST is a consultant for Almirall, Bayer, Beiersdorf, Bionorica, Cara Therapeutics, Celgene, DS Biopharma, Galderma, Kneipp, Menlo Therapeutics, NeRRe Therapeutics, Novartis, Perrigo, Sienna Therapeutics, ACO HUD Nordic, Toray, Sanofi, Trevi Therapeutics, Bellus Health and an investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Trevi Therapeutics, Novartis. TB is an advisor for Menlo Therapeutics (products may be related) and Novartis (unrelated).
Funding source
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.16309